Premium
Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors
Author(s) -
Drenberg C D,
Baker S D,
Sparreboom A
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.247
Subject(s) - clinical pharmacology , pharmacology , medicine , tyrosine kinase , tyrosine kinase inhibitor , clinical practice , clinical trial , receptor , cancer , family medicine
Tyrosine kinases have emerged as important tumor targets for the design of potent and selective inhibitors. Eighteen of these tyrosine kinase inhibitors (TKIs) have already been approved for the treatment of diseases that were previously essentially resistant to standard chemotherapy. Major efforts are ongoing that focus on the development of companion diagnostics for investigational and approved TKIs, as well as on integrating clinical pharmacology principles in clinical practice to decrease toxicity and improve efficacy. Clinical Pharmacology & Therapeutics (2013); 93 3, 215–219. doi: 10.1038/clpt.2012.247